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Intragraft TGF-131 mRNA: A correlate of interstitial fibrosis and
chronic allogratt nephropathy. Chronic allograft ncphropathy is a relent-
lessly progressive process and a major cause of long-term graft dysfunction
and ultimate failure. Interstitial fibrosis, tubular atrophy, and gloinerular
and vascular lesions characterize this mechanistically unresolved disorder.
Given the prominent role of TGF-j31 in tissue repair and in fibrosis, we
have explored the hypothesis that fibrosis and chronic allograft nephrop-
athy would be distinguished by intragratt TGF-p1 mRNA expression. This
postulate was tested by mRNA phenotyping of RNA isolated from 127
human renal allograft biopsies. Reverse transcription assisted polymerase
chain reaction was used to amplity and identity ingraft gene expression.
Our investigation demonstrated a significant correlation between intra-
graft TGF-1 mRNA display and renal allograft interstitial fibrosis and
chronic allograft nephropathy. In contrast, intragraft expression of mRNA
encoding immunoregulatory cytokines, IL-2, IFN-y, IL-4, IL-b, or cyto-
toxic attack molecules, granzyme B and perfnrin was not a correlate of
interstitial fibrosis or chronic allograft nephropathy. Our studies identify,
for the first time, a significant association between intragraft TGF-p1
mRNA expression and renal allograft interstitial fibrosis, and advance a
candidate molecular mechanism for chronic allograft nephropathy.
Renal transplantation is the treatment of choice for most
patients afflicted with end-stage renal disease. A steady improve-
ment in the outcome of renal allografts has bccn noted, especially
those of cadaveric origin and those involving second or subse-
quent transplantations. In 1988, the one year graft survival rate
among 6073 primary, 954 second, and 173 subsequent cadaveric
grafts, was 77.4%, 69.4% and 58.5%, respectively; in 1993, thc rate
had improved to 83.9% for 6,991 primary grafts, 81.2% for 855
second grafts, and 72.fi% for 151 subsequent grafts [fl. Improved
understanding of the anti-allograft response, refined usagc of
cyclosporine (CsA), selectivc application of monoclonal or poly-
clonal antibodies, and the routine use of infection prophylaxis
protocols have all contributed to the gratifying short-term results
reported following renal transplantation.
The advances in the treatment strategies, however, have had
modest impact on the long-term outcome following renal trans-
plantation. The half-life (the time needed for 50% of the grafts
functioning 1 year after transplantation to fail) of cadaverie renal
allografts has increased from about eight years in 1988 to only
about 10 years in 1992 [1J. The most common cause of failure
of long-term allografts, chronic allograft rejeetion/nephropathy
[2—41, remains poorly understood with respect to underlying
molecular and immunologic mechanism(s). Antigen specific cel-
lular and humoral immunity, additional cellular elements, includ-
ing maerophages and platelets (and their secretory products,
eieosanoids), and non-immune factors such as dyslipidemia and
hypertension have all been hypothesized as pathogenic factors
12—41.
Histopathological features associated with progressive allograft
dysfunction have been described [5, 61. The pertinent morpholog-
iealalterations include interstitial fibrosis, increased extracellular
matrix accumulation, and glomerular and vascular lesions.
In this investigation, we have explored the hypothesis that
intragraft expression of transforming growth factor-p1 (TGF-p5)
is a correlate of interstitial fibrosis and chronic allograft nephrop-
athy in human renal allografts. TGF-p1, a 25 kDa homodimerie
secretory product of many cell lines including platelets, T cells,
mesangial cells and monocytes/macrophages, is a multifunetional
cytokine [reviewed in 7, 8]. It is a prominent member of the
eytokine cascade involved in tissue repair, and considerable data
support its fibrogenie properties. Some of the biological proper-
ties of this pluripotent eytokine include its ability to promote the
production of extracellular matrix materials (fibroneetin, collag-
ens and proteoglycans), enhance the expression of integrins, and
reduce the activities of matrix degrading proteases [7, 8].
The data from this investigation of intragraft gene expression in
human renal allograft recipients demonstrate a significant corre-
lation between intragraft expression of TGF-p1 mRNA and
interstitial fibrosis and chronic allograft nephropathy. Moreover,
the specificity of this association is emphasized by the lack of
correlation between histologic features of either interstitial fibro-
sis or chronic allograft nephropathy and intragraft display of type
I cytokines (IL-2, IFN-y), type II cytokines (IL-4 and IL-b), and
cytotoxie attack molecules (granyme B and perform).
Methods
Subjects
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One hundred twenty-seven renal allograft core tissue samples
were obtained from 107 patients who received their renal al-
lografts at our institutions, The New York Hospital (New York
City, NY, USA; N = 71), or Hennepin County Medical Center
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(Minneapolis, MN, USA; N = 36). Eighty-eight patients under-
went one biopsy each; 18 recipients, two biopsies, and one patient
underwent three renal biopsies. The biopsies were performed for
clinical reasons to determine the basis for graft dysfunction. The
renal allograft recipients were managed with an immunosuppres-
sive regimen of antilymphocyte antibodies and/or cyclosporine,
prednisone and azathioprine [91.
Histopathological evaluation of renal allograft biopsy specimens
The biopsy tissues included in this study of intragraft gene
expression were classified on the basis of the Banif working
classification criteria [6]. The tissue samples, in each instance,
were considered adequate for diagnostic purposes; at least three
slides stained with H and E, and four samples with special stains
(PAS, trichrome, Azan and silver stain) were examined [6]. The
histological classification of the biopsy specimen was made with-
out the knowledge of the results of the molecular studies. The
following criteria and grading were used for the histopathological
diagnosis of renal allograft biopsy specimens.
Interstitial fibrosis and tubular atrophy. The following features
were utilized and were considered independent of possible etiol-
ogy of interstitial fibrosis (such as chronic rejection, chronic CsA
toxicity and/or chronic ischemic injury). The separation of the
tubules by increased interstitial connective tissue and fibrosis was
observed and confirmed by Azan or trichrome stain. Interstitial
fibrosis was graded on a scale of 0, 1, 2, and 3, based on the
severity of the observed lesion [6]. The tubules showing wrinkling
and thickening of the tubular basement membrane were detected
with the PAS stain and the degree of tubular atrophy was also
graded on a scale of 0, 1, 2, and 3, as proposed in the Banif
classification [6]. The extent of fibrosis usually paralleled that of
tubular atrophy.
Chronic allograft nephropathy. The histologic diagnosis was
based on the presence of interstitial fibrosis and tubular atrophy
and additional vascular changes including arterial fibrous intimal
thickening, and glomerular changes such as glomerular tuft
shrinkage, sclerosis and thickening or wrinkling of the basement
membrane. The glomerular changes, interstitial fibrosis, tubular
atrophy and vascular changes were graded on a scale of 0, 1, 2 and
3, as proposed [6].
Acute rejection. The histologic diagnosis of acute rejection was
based on the presence of significant interstitial infiltration by
lymphocytes, and invasion of tubules (tubulitis) and/or the walls of
blood vessels (intimal arteritis) [6].
CsA-associated changes. Isometric vacuolization of tubules,
eosinophilic inclusions, microcalcification, hyaline arteriolar thick-
ening and striped or patch fibrosis were identified by light micros-
copy and considered as features of CsA associated changes [6].
Molecular studies of renal allograft biopsy specimens:
RNA isolation
Portions of renal biopsy tissue were snap-frozen in liquid
nitrogen and stored at —70°C for later RNA extraction. The renal
tissue was homogenized with a tissue tearer in 4 M guanidinium
isothiocyanate solution and loaded on top of 5.7 M CsCl cushion
and centrifuged at 20°C and 50,000 rpm for 16 to 20 hours using
a TLS 55 rotor in a Beckmann TL100 ultracentrifuge. RNA was
isolated as described previously [101 and quantified by spectro-
photometry.
Reverse transcription assisted PCR. Reverse transcription as-
sisted PCR was done as previously described [10]. In brief, 1 g of
total RNA was reverse-transcribed into eDNA in a 20-l reaction
mixture containing 50 mM Tris-HC1 (pH 8.3); 75 mrvt KC1; 10 mM
DTT; 3 mi MgCI2; 200 units of Moloney murine leukemia virus
reverse transcriptase, 100 nglreaction of random hexanucleotide
primers, and 0.5 m each of deoxyribonucleoside triphosphatases
(dNTPs): dATP, dCTP, dGTP, and dYTP. The reaction mixtures
were incubated at 37°C for one hour and then incubated at 65°C
for 10 minutes to deactivate the reverse transcriptase. The final
volume was adjusted to 50 l with TE buffer (pH 8.0) and the
cDNAs were stored at —20°C till further analysis. A 3 jd of cDNA
from a total of 50 d was amplified with 1 unit of Taq DNA
polymerase in a final volume of 50 .d containing 10 mM Tris-HC1
(pH 8.3), 50 mM KC1, 1.5 mrvi MgCI2 0.01% gelatin, 40 .LM of each
dNTP, and 0.2 JLM of each primer. Thirty-five cycles of amplifica-
tion were carried out in a thermocycler (Gene Amp PCR System
9600, Perkin Elmer, CA, USA), and the amplification profile was
as follows: denaturing at 94°C for 30 seconds, primer annealing at
57°C for 30 seconds, and primer extension at 72°C for 30 seconds.
Before cycling, the samples were preheated at 94°C for 30
seconds, and after amplification an extra five minutes were added
for extension at 72°C. Aliquots (8 tl) of each resulting PCR
product were applied to a 2% NuSieve agarose/1% agarose gel,
resolved by electrophoresis, visualized by ethidium bromide stain-
ing, and photographed.
Design and synthesis of sequence specific oligonucleotide primers
Table 1 lists the sequence of the oligonucleotide primers used
to amplify mRNA encoding cytokines, cytotoxic attack molecules,
and the constitutively expressed -actin mRNA. The predicted
size of the PCR product generated with a particular primer pair is
also listed in Table 1. The primers were designed to flank an
intron site in the target sequence. This primer design permits
detection of genomic contamination of the RNA preparation
from the renal biopsy specimens. Also, in each instance, /3-actin
mRNA was amplified as an internal control for reverse transcrip-
tion assisted PCR [10].
Statistical analysis
Fisher's Exact Test for 2 x 2 tables was used to assess the
correlation between intragraft mRNA expression and histopatho-
logical diagnosis. Sensitivity, specificity, and positive and negative
predictive values were also calculated when a statistically signifi-
cant correlation (P < 0.05) between intragraft mRNA expression
and a specific renal histological diagnosis was observed. Mann-
Whitney two sample test was used to determine two-tailed P
values following comparison of the mean scores of glomerular,
vascular, tubular changes and the severity of interstitial fibrosis in
biopsies distinguished by the presence or absence of intragraft
mRNA expression.
Results
Histological classification of renal allograft biopsies
Figure 1 illustrates the histological diagnosis of renal biopsies
classified on the basis of Banif working classification criteria [6].
Among the 127 biopsies, 67 were classified as acute rejection, 20
as chronic allograft nephropathy, 16 as chronic allograft nephrop-
athy and acute rejection, 13 as CsA associated changes. Among
Table 1. Sequences of oligonucleotide primers used in RT-PCR
(Nature 316:701—705, 1985)
CTG COG ATC TCT GTG TCA UT
CTC AGA GTG UTO CTA TGG TG
(PNAS 80: 7437—7441, 1983)
CCT CTG GAG GAA GTG CTA AA
ATG GTE GCT GTC TCA TCA GC
(Nature 298:859—863, 1982)
GCA GGT CAT TCA GAT GTA GC
TFC CUT OAT GGT CTC CAC AC
(PNAS 83:5894—5898, 1986)
'fEC TAC AGC CAC CAT GAG AAG
CAG CTC GAA CAC TflT GAA TAT
(PNAS 88:1172—1176, 1991)
TAA GGG T]TA CCT GGG TVFG CCA A
cTAC TCA TGG TI1T TOT AGA TGC C
(Immunogenetics 30:452—457, 1989)
CAG TAC AGC 'fEC AGC ACT GAC
ATG AAG TGG GTG CCG TAG TI1TG
(Gene 87:265—271, 1990)
TGC AGG AAG ATC GAA AGT GCG
GAG GCA TGC CAT TGT TITC GTC
(PNAS 82:6133—6137, 1985)
GGT CAC CCA CAC TGT GCC CAT
GGA TGC CAC AGO ACT CCA TGC
CSA (N=13)
Other (N=1 1)
CAN (N=20)
Fig. 1. Histopathological diagnosis of renal
allograft biopsy specimens. The histological
diagnosis of renal allograft biopsy samples were
based on Banif working classification criteria
for diagnosing kidney transplant pathology [6].
Abbreviations are: AR, acute rejection (N =
67); AR + CAN, acute rejection plus chronic
allograft nephropathy (N = 16); CAN, chronic
allograft nephropathy (N = 20); CsA, CsA
associated changes (N = 13); Other, non-
specific changes (N = 2); ATN (N = 2);
normal (N = 2), recurrent renal disease (N =
4), and de novo glomerular disease (N = 1).
The numbers (N) represent the number of
tissue samples.
the 36 biopsies classified as chronic allograft nephropathy, 23
displayed features of transplant glomerulopathy [6], and among
13 biopsies classified as CsA associated changes, 11 displayed
features of arteriolopathy [6]. Of the 11 renal biopsies classified as
other, 4 expressed histological features of recurrent renal disease;
2 revealed non-specific morphological alterations, 2, ATN, 2,
normal, and one was de novo glomerular disease (Fig. 1).
Interstitial fibrosis was observed in 87 of the 127 biopsy
specimens. Table 2 lists the histological diagnosis of the biopsies
distinguished on the basis of presence or absence of interstitial
fibrosis.
Intragraft TGF.j31 mRNA expression in renal allograft interstitial
fibrosis and chronic allograft nephropathy
TGF-/3 is a potent fibrogenic cytokine with a prominent role in
tissue repair following injury. This pluripotent cytokine induces an
increase in extraeellular matrix materials [7, 8]. Given that
allografts are targets of multiple insults (ischemia, rejection and
drugs) and given the prominent feature of fibrosis in chronic
allograft nephropathy [61, we determined the correlation between
AR AR + CAN CAN CsA Other
Present 35 16 20 10 6
(N = 87)
Absent 32 0 0 3 5
(N = 40)
intragraft TGF-/31 mRNA expression and renal allograft intersti-
tial fibrosis and chronic allograft nephropathy.
Table 3 shows the significant correlation between intragraft
expression of intragraft TGF-131 mRNA and interstitial fibrosis.
The association between intragraft TGF-131 mRNA expression
and interstitial fibrosis was significant at P 0.03 by Fischer's
Exact Test.
Additional analysis of the correlation revealed that the sensi-
tivity of intragraft TGF-f31 mRNA expression was 0.61 and the
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TGF-f31
5'Sense
3'Antisense
IL-2
5 'Sense
3'Antisense
IFN-y
5' Sense
3'Antisense
IL-4
5'Sense
3'Antisense
IL-lU
5'Sense
3'Antisense
Perform
5'Sense
3 'Antisense
Granzyme B
5'Sense
3'Antisense
f3-Actin
5 'Sense
3'Antisense
(2154-2173) 246 bp
(2380.2399)
(3113-3132) 149 bp
(5087-5 106)
(1831-1850) 177bp
(2083-2102)
(298-318) 227 bp
(504-524)
(252-273) 257 bp
(487-508)
(496-516) 176 bp
(65 1-671)
(3360.3380) 180 bp
(4163-4183)
(2139-2159) 350 bp
(2563-2583)
AR (N=67) AR + CAN (N=16)
Table 2. Histological diagnosis of renal allograft biopsies distinguished
by the presence or absence of interstitial fibrosis
Interstitial
fibrosis
Histological Classification
Abbreviations are: AR, acute rejection; CAN, chronic allograft ne-
phropathy; CsA, cyclosporine associated morphological changes.
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Table 3. Correlation between intragraft mRNA expression and renal
allograft interstitial fibrosis
Intragraft mRNAa
Renal allograft fibrosis
+
(N = 87) (N = 40) pb
TGF-/31 mRNA
IL-2 mRNA
IFNy rnRNA
IL-4 mRNA
IL-lO mRNA
Granzyme B mRNA
Perform mRNA
+
—
+
—
+
—
+
—
+
—
+
—
+
—
(69)
(58)
(10)
(117)
(56)
(66)
(2)
(85)
(55)
(72)
(76)
(51)
(49)
(77)
53 16
34 24
7 3
80 37
38 18
44 22
2 0
55 30
36 19
51 21
50 26
37 14
38 11
48 29
0.03
1.00
0.99
0.54
0.56
0.44
0.08
a Total RNA was isolated and reverse transcribed into eDNA and am-
plified by PCR with the sequence specific primer pairs listed in Table 1
bTwo-tailed P value derived with Fischer's Exact Test for 2 X 2 tables
specificity was 0.60. The positive predictive value was 0.77 and the
negative predictive value was 0.41.
Among the 87 biopsies distinguished by the presence of inter-
stitial fibrosis, 36 biopsies displayed histopathological features of
chronic allograft nephropathy. Twenty-six of the 36 biopsies
classified as chronic allograft nephropathy were positive for
intragraft TGF-p1 mRNA expression. The significant correlation(P = 0.01, Fischer's Exact Test) between intragraft TGF-f31
mRNA expression and chronic allograft nephropathy is shown in
Table 4.
Additional evaluation of the correlation between intragraft
TGF-131 mRNA expression and chronic allograft nephropathy
revealed that the sensitivity of intragraft TGF-f31 mRNA expres-
sion was 0.72, and the specificity was 0.53. The positive predictive
value was 0.38, and the negative predictive value was 0.83.
Quantitative assessment of morphological changes revealed
significant differences between the intragraft TGF-p1 mRNA
positive group and theTGF-/31 mRNA negative group with re-
spect to severity of interstitial fibrosis and tubular changes. The
mean SEM score of interstitial fibrosis in the TGF-f31 mRNA
positive group was 1.33 0.13 (N = 69 biopsies) and was 0.94
0.13 (N = 58) in the TGF-/31 mRNA negative group; the
difference was significant at P = 0.04 by Mann-Whitney two
sample test. The mean SEM score of tubular atrophy in the
TGF-j3, mRNA positive group was 1.18 0.12, and in the
negative group, 0.77 0.10 (P = 0.03). The mean scores for the
chronic glomerular changes, and for the chronic vascular changes
were also higher in the intragraft TGF-p1 mRNA positive group
compared to the negative group (chronic glomerular changes, 0.59
0.11 vs. 0.36 0.10; and chronic vascular changes, 0.55 0.10
vs. 0.44 0.11). These differences, however, were not statistically
significant by Mann-Whitney two-sample test.
Intragraft expression of IL-2 mRNA or IFN-y mRNA in interstitial
fibrosis and chronic allograft nephropathy
IL-2 is a prototypic T-cell growth factor that promotes T-cell
immune responses (such as cytotoxic T cell generation [11]),
Table 4. Correlation between intragraft mRNA expression and chronic
allograft nephropathy
Chronic allograft
nephropathy
+
Intragraft mRNAa (N = 36) (N = 91) F'
TGF-/31 mRNA
IL-2 mRNA
IFNy mRNA
IL-4 mRNA
IL-b mRNA
Granzyme B mRNA
Perform mRNA
+
—
+
—
+
—
+
—
+
—
+
—
+
—
(69)
(58)
(10)
(117)
(56)
(66)
(2)
(85)
(55)
(72)
(76)
(51)
(49)
(77)
26 43
10 48
2 8
34 83
15 41
19 47
0 2
22 63
12 43
24 48
19 57
17 34
17 32
19 58
0.01
0.72
0.84
0.61
0.16
0.32
0.31
Total RNA was isolated and reverse transcribed into eDNA and am-
plified by PCR with the sequence specific primer pairs listed in Table 1b Two-tailed P value derived with Fischer's Exact Test for 2 X 2 tables
considered detrimental to the well-functioning of allografts.
IFN-y is a proinfiammatory polypeptide that enhances not only
immune effector mechanisms but also the display of HLA-
proteins, the primary targets of anti-allograft responses [12]. IL-2
and IFN-y are products of T helper type 1 cells. We [13] and
others [14] have reported that intragraft expression of IL-2
mRNA is a correlate of acute rejection of human renal allografts.
Given the prominent role of these cytokines in host immune
assault responses, we sought to determine whether intragraft
expression of IL-2 mRNA or IFN-y mRNA is also a correlate of
allograft interstitial fibrosis and chronic allograft nephropathy.
Table 3 shows that intragraft expression of IL-2 mRNA or
IFN-y mRNA is not a significant correlate of renal interstitial
fibrosis. The correlation between intragraft expression of these
proinflammatory cytokines and chronic allograft nephropathy is
also not significant (Table 4).
Intragraft expression of IL-b mRNA or IL-4 mRNA in interstitial
fibrosis and chronic allograft nephropathy
IL-b, originally designated as cytokine synthesis inhibitory
factor, has multiple effects on the immune system, including
promotion of B-cell dependent immunity [15]. Indeed, in our
earlier study of intragraft gene expression, a significant correlation
was found between intragraft IL-b mRNA expression and acute
rejection [13]. Since chronic allograft nephropathy/rejection might
be a consequence of repetitive immune injury, we determined
whether intragraft expression of IL-b mRNA is a correlate of
interstitial fibrosis and/or chronic allograft nephropathy. We also
determined whether IL-4, a multifunctional cytokine with a
prominent role in immune regulation [161, is a molecular correlate
of renal allograft interstitial fibrosis and/or chronic allograft
nephropathy.
Results found by amplifying the IL-b mRNA or IL-4 mRNA
by reverse transcription assisted PCR are shown in Tables 3 and
4. It is evident that neither the intragraft expression of IL-b
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mRNA nor the intragraft expression of IL-4 mRNA is a signifi-
cant correlate of either renal allograft interstitial fibrosis (Table 3)
or chronic allograft nephropathy (Table 4).
Intragraft expression of granzyme B mRNA or perform mRNA in
interstitial fibrosis and chronic allograft nephropathy
Elegant studies have demonstrated that intragraft expression of
CTL-specific serine protease, granzyme B, is a significant corre-
late of human renal allograft rejection [17]. Data also exist to
show that the pore-forming protein, perform, is a major partici-
pant in the lytic machinery of CTL [18]. Recent studies have also
emphasized the importance of an earlier acute rejection episode
to subsequent occurrence of chronic rejection [19]. The possibility
thus exists that chronic allograft nephropathy/rejection might be
due to CTL-dependent cellular effector mechanism(s). In light of
these considerations, we determined whether intragraft expres-
sion of granzyme B mRNA or perform mRNA is a molecular
correlate of allograft fibrosis and/or chronic allograft nephropa-
thy.
Results found by amplifying eDNA with a granzyme B sequence
specific primer pair or a perform sequence specific primer pair,
are shown in Tables 3 and 4. Unlike the significant correlation
found between intragraft TGF-p1 mRNA expression and renal
interstitial fibrosis and chronic allograft nephropathy, and in a
fashion similar to the lack of correlation between intragraft
expression of mRNA encoding IL-2, IFN-y, IL-4 or IL-tO and
allograft fibrosis or chronic allograft nephropathy, intragraft
expression of granzyme B mRNA or perform mRNA was not a
correlate of either renal allograft interstitial fibrosis (Table 3) or
chronic allograft nephropathy (Table 4).
Discussion
The new finding that has emerged from this investigation is that
intragraft expression of mRNA encoding TGF-131 is a significant
correlate of human renal allograft interstitial fibrosis and chronic
Fig. 2. Schema for the pathogenesis of chmnic
allograft nephropathylrejection. In this fibrogenic
cytokine hypothesis, intrarenal expression of
TGF-J31 represents a significant pathogenetic
molecular event for the expression of chronic
allograft nephropathy/rejection. The ability of
TGF-131 to promote its own production
(positive feedback loop), and its additional
properties (such as regulation of PDGF activity,
stimulation of endothelin-1 production) are also
incorporated into this framework. That two of
the most commonly used drugs in
transplantation, CsA and steroids, stimulate
TGF-131 expression is also considered in this
formulation regarding the cascade of events
involved in chronic allograft
nephropathy/rejection.
allograft nephropathy. This original observation also emphasizes
the specificity of the association between intragraft TGF-(31
mRNA display and graft fibrosis and chronic allograft nephropa-
thy. Whereas intragraft TGF-/31 mRNA expression is significantly
associated with the fibrosis and chronic allograft nephropathy,
other immune regulatory cytokines (IL-2, IFN-y, IL-4 and IL-b)
and potent mediators of cytotoxicity (granzyme B and perform)
are not significant correlates.
Significance of intragraft TGF-131 mRNA expression
A number of well-characterized biological properties of
TGF-f3, support the hypothesis that intragraft expression of
TGF-/31 might be mechanistically linked to the fibrotic process
observed in the allograft. The relevant activities include: (a)
stimulation of the production of extracellular matrix materials,
fibronectin, collagens and proteoglycans [7, 8]; (b) promotion of
the production of protease inhibitors such as plasminogen activa-
tor inhibitor type 1; (c) enhancement of the expression of
matrix-anchoring proteins such as integrins; and (d) reduction in
the activity of matrix-degrading proteins such as plasminogen
activator [7, 8].
Evidence that TGF-131 engenders in vivo renal disease and fibrosis
In a rodent model of glomerulonephritis induced with a single
injection of antithymocyte serum, intrarenal expression of TGF-13
was found to be associated with increased extracellular matrix
accumulation; also, anti-TGF- antibodies or proteoglycans (nat-
ural regulators of TGF-p activity) constrained the production and
accumulation of extracellular matrix material in this rodent model
[8]. In the multiple injection model, sustained intrarenal expres-
sion of TGF-f31 was observed and such persistent expression was
associated with tubulointerstitial fibrosis and glomerulosclerosis
[8]. Direct evidence that TGF-131 induces renal sclerosis has also
been obtained. Isaka et a! [20] have demonstrated that in vivo
transfection of TGF-f31 gene into the rat kidney results in
V
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glomeruloscierosis. In this elegant study, transfection of the gene
encoding platelet-derived growth factor resulted in the prolifera-
tion of glomerular cells only, and not in a major increase in
extracellular matrix materials. Experimental data from rats made
diabetic with the islet cell toxin streptozocin [81, and clinical data
from diabetic patients with renal disease or mesangial prolifera-
tive glomerulonephritis, also support the hypothesis that TGF-131
is associated with increased extracellular matrix accumulation and
fibrosis. In this regard, it is noteworthy that the expression of
TGF-13 is stimulated by hyperglycemia [211 as well as by angio-
tensin II (Ang II) [22], and that the strict control of blood glucose
or the inhibition of Ang II generation retards the progression of
diabetic renal disease [23, 24].
Mechanistic and clinical implications of intragraft TGF-p1
mRNA expression
Our data, viewed in the context of earlier data that TGF-/31
participates in the expression of experimental or clinical renal
disease states characterized by fibrosis, provide a molecular
mechanism for the interstitial fibrosis associated with chronic
allograft rejection/nephropathy. As schematically shown in Figure
2, it can be hypothesized that allograft injury results in TGF-p1
expression, given its prominent role in tissue repair. TGF-/31 then
engenders interstitial fibrosis by virtue of its ability to promote
extracellular matrix material accumulation and fibroblast prolif-
eration. In addition to ischemia and rejection causing allograft
injury, immunosuppressive therapy might also contribute to a!-
lograft injury since CsA [10] as well as steroids [25] stimulate
TGF-131 expression. This unique effect of these two drugs widely
used in clinical transplantation, coupled with our demonstration
that the cytokines whose expression is suppressed by CsA or
steroids (such as IL-2, IFN-y) are not correlates of interstitial
fibrosis and chronic allograft nephropathy, provides an explana-
tion for the lack of a therapeutic benefit observed with CsA or
steroids in the management of chronic allograft nephropathy/
rejection.
TGF-/31 stimulates its own production via specific response
elements located in the TGF-J31 promoter region [26]. Thus, a
self-perpetuating process contributing to further progression of
renal lesions can be entertained. Additional cytokine/polypeptide
regulated mechanisms can also be considered. For example,
TGF-131 regulates not only the expression of cytokines like PDGF
and fibroblast growth factor but also that of the potent vasocon-
strictor, endothelin-1 [27]. This cascade of events, viewed in the
context of the progressive nature of renal disease due to intrarenal
hemodynamic mechanisms [28], provides a conceptual framework
for the relentlessly progressive nature of chronic allograft rejec-
tion/nephropathy.
Elegant experimental data exist that antibodies directed at the
TGF-J3 protein or the proteoglycans prevent TGF-13-associated
renal disease [81. We have constructed a novel deoxynucleotide
antigene oligomer complementary to the TGF-/31 promoter DNA
that prevents TGF-f31 expression [29]. The new observation from
the current investigation, that intragraft TGF-131 expression is a
molecular correlate of renal allograft interstitial fibrosis and
chronic allograft nephropathy, considered with the paucity of
effective therapy for chronic rejection, suggests that the above-
mentioned strategies might be of therapeutic value in preventing
the development of and/or constraining the progression of chronic
allograft nephropathy.
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